Q&A: A missing conversation on the price of cancer drugs

A novel approach to judge which new cancer drugs are worth reimbursing is emerging within the European Organisation for Research and Treatment of Cancer, an independent research group. Denis Lacombe, its director general, says the growing understanding of tumor biology can equip European authorities to make more informed decisions based on performance in real-life conditions. In an interview with POLITICO, he suggested how to ease access to the evidence that could radically improve decision-making.

The read the full article on the Politico Pro website.

Back to news list